Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma
Clinical trial NCT00597272 · COMPLETED
Trial details
- NCT number
- NCT00597272
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- COMPLETED
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2007-12-01
- Primary completion
- 2012-11-01
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.